We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Places Clinical Hold on Second Idenix Hepatitis Drug

FDA Places Clinical Hold on Second Idenix Hepatitis Drug

August 31, 2012

The FDA has placed a “precautionary” clinical hold on Idenix Pharmaceuticals’ next-generation nucleotide polymerase inhibitor, IDX19368, being developed to treat hepatitis C (HCV) infection.

This is the second clinical hold in a month for Idenix’s hep C program, as the FDA just put a partial hold on IDX184, which was already in clinical trials. No patients have received IDX19368.

Both holds follow adverse heart events seen in Bristol-Myers Squibb (BMS) trials of a similar drug, BMS-986094.

“We understand the clinical hold is a precautionary decision,” Idenix President and CEO Ron Renaud said. Although the Idenix and BMS drugs share the same active metabolite, “there are many attributes of our compounds … that we believe favorably differentiate the toxicity profiles,” he added.

BMS has agreed to share relevant information on its drug with Idenix, “and we hope this helps us to resolve this issue quickly,” Renaud said. Idenix had planned to begin clinical trials in the third quarter of 2012.

In response to major safety-related drug withdrawals, Congress has given FDA greater authority in pharmaceutical safety regulation. Add in the soon-to-be-implemented pharmacovigilance measures in the EU and sponsors’ jobs have never been tougher.

Even if you think you know the FDA’s latest thinking on clinical trial safety, postmarketing pharmacovigilance, adverse event reporting and REMS, you could be working under false assumptions — using outdated practices that could set you up for serious penalties.

But over two days in either Boston or Philadelphia, you can dive into a workshop that will enhance your safety signal detection, evaluation and management skills. Register today for FDAnews’ Safety Signal Detection, Evaluation and Associated Actions: Assessing and Managing Risk Throughout the Drug and Biologics Lifecycle.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Eli Lilly logo

    Lilly’s Monoclonal Antibody Could Prevent COVID-19 in the Elderly

  • CE mark

    Fluidigm Gains CE Mark for Saliva-Based Assay for COVID-19

  • Regeneron logo

    Regeneron’s Antibody Cocktail Shows Efficacy as COVID-19 Treatment

  • Mobile apps client cellphone cell phone

    FDA to Review Berkshire’s 510(k) Submission for Remote Drug-Delivery System

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing